BRPI1012203A2 - derivados de 5-piridin-3-il-1,3-di-hidro-indol-2-ona e seu uso como moduladores da aldosterona sintase e/ou da cyp11b1 - Google Patents

derivados de 5-piridin-3-il-1,3-di-hidro-indol-2-ona e seu uso como moduladores da aldosterona sintase e/ou da cyp11b1

Info

Publication number
BRPI1012203A2
BRPI1012203A2 BRPI1012203A BRPI1012203A BRPI1012203A2 BR PI1012203 A2 BRPI1012203 A2 BR PI1012203A2 BR PI1012203 A BRPI1012203 A BR PI1012203A BR PI1012203 A BRPI1012203 A BR PI1012203A BR PI1012203 A2 BRPI1012203 A2 BR PI1012203A2
Authority
BR
Brazil
Prior art keywords
cyp11b1
indol
pyridin
modulators
dihydro
Prior art date
Application number
BRPI1012203A
Other languages
English (en)
Inventor
Christopher Michael Adams
Chun Zhang
Qi-Ying Hu
Sylvie Chamoin
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI1012203A2 publication Critical patent/BRPI1012203A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI1012203A 2009-05-15 2010-05-12 derivados de 5-piridin-3-il-1,3-di-hidro-indol-2-ona e seu uso como moduladores da aldosterona sintase e/ou da cyp11b1 BRPI1012203A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17868409P 2009-05-15 2009-05-15
US32721810P 2010-04-23 2010-04-23
PCT/EP2010/056569 WO2010130794A1 (en) 2009-05-15 2010-05-12 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or cyp11b1

Publications (1)

Publication Number Publication Date
BRPI1012203A2 true BRPI1012203A2 (pt) 2016-04-05

Family

ID=42342893

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1012203A BRPI1012203A2 (pt) 2009-05-15 2010-05-12 derivados de 5-piridin-3-il-1,3-di-hidro-indol-2-ona e seu uso como moduladores da aldosterona sintase e/ou da cyp11b1

Country Status (11)

Country Link
US (2) US8778972B2 (pt)
EP (1) EP2430011A1 (pt)
JP (1) JP2015034187A (pt)
KR (1) KR20120023091A (pt)
CN (1) CN102459223B (pt)
AU (1) AU2010247412A1 (pt)
BR (1) BRPI1012203A2 (pt)
CA (1) CA2761858A1 (pt)
EA (1) EA201101619A1 (pt)
MX (1) MX2011012202A (pt)
WO (1) WO2010130794A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102007007751A1 (de) * 2007-02-16 2008-08-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
DE102007035333A1 (de) * 2007-07-27 2009-01-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel
ES2461799T3 (es) * 2008-01-22 2014-05-21 Vernalis (R&D) Ltd. Derivados de indolil-piridona que tienen actividad inhibidora de la quinasa de control 1
ES2430088T3 (es) 2009-05-15 2013-11-18 Novartis Ag Derivados de benzoxazolona como inhibidores de aldosterona sintasa
EA201101619A1 (ru) 2009-05-15 2012-05-30 Новартис Аг Производные 5-пиридин-3-ил-1,3-дигидроиндол-2-она и их применение в качестве модуляторов альдостеронсинтазы и/или cyp11b1
ES2663351T3 (es) 2009-11-17 2018-04-12 Novartis Ag Derivados de aril-piridina como inhibidores de la aldosterona sintasa
JP6263469B2 (ja) 2011-07-15 2018-01-17 ノバルティス アーゲー アザ二環式ジ−アリールエーテルの塩およびその製造方法またはその前駆体の製造方法
WO2013079452A1 (en) * 2011-11-30 2013-06-06 F. Hoffmann-La Roche Ag New bicyclic dihydroisoquinoline-1-one derivatives
ES2655066T3 (es) * 2012-04-17 2018-02-16 F. Hoffmann-La Roche Ag Nuevos derivados de fenil-tetrahidroisoquinolina
EP2903615B1 (en) * 2012-10-05 2021-04-07 Merck Sharp & Dohme Corp. 5-pyridin-3-yl-2,3-dihydro-1h-indole derivatives as aldosterone synthase (cyp11b2) inhibitors for the treatment of hypertension
CA2914132A1 (en) 2013-06-21 2014-12-24 Lupin Limited Substituted heterocyclic compounds as crac modulators
US9790231B2 (en) 2013-06-24 2017-10-17 Lupin Limited Chromane and chromene derivatives and their use as CRAC modulators
CN104530000B (zh) * 2014-12-12 2016-07-20 重庆博腾制药科技股份有限公司 一种醛固酮合酶调节剂中间体的制备方法
CN104496885B (zh) * 2015-01-12 2017-08-25 中国药科大学 一种n‑甲基‑4‑氨基‑5‑硝基靛红的制备方法
BR112019018700A2 (pt) 2017-03-10 2020-04-07 Embera Neurotherapeutics Inc composições farmacêuticas e seus usos
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
CN111315735B (zh) * 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
US11547712B2 (en) 2017-11-20 2023-01-10 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US11788064B2 (en) 2018-01-05 2023-10-17 Icahn School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
CA3093340A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
EP3906233B1 (en) * 2018-12-31 2024-01-31 Icahn School of Medicine at Mount Sinai Kinase inhibitor compounds and compositions and methods of use
WO2020181232A1 (en) 2019-03-06 2020-09-10 C4 Therapeutics, Inc. Heterocyclic compounds for medical treatment

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE425142T1 (de) 1999-04-23 2009-03-15 Vertex Pharma Inhibitoren von c-jun n-terminal kinasen (jnk)
US20030187026A1 (en) 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
EP1492568A1 (en) 2002-04-08 2005-01-05 SmithKline Beecham Corporation Cancer treatment method comprising administration of an erb-family inhibitor and a raf and/or ras inhibitor
US9259390B2 (en) 2003-08-13 2016-02-16 The University Of Houston System Parenteral and oral formulations of benzimidazoles
CA2554774A1 (en) 2004-02-23 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. Novel heterocyclic compound
JP2008524246A (ja) 2004-12-16 2008-07-10 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
GT200600179A (es) 2005-04-29 2006-11-22 Proceso para preparar oxindoles y tio-oxindoles 3,3-disustituidos
PE20070220A1 (es) 2005-07-29 2007-03-19 Wyeth Corp Proceso para la sintesis de moduladores del receptor de progesterona
PE20070519A1 (es) 2005-08-25 2007-07-13 Schering Corp Derivados de fenilmorfolina y feniltiomorfolina como agonistas de adrenoreceptores alfa 2c
EP2187883A2 (en) 2007-08-10 2010-05-26 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
ES2430088T3 (es) 2009-05-15 2013-11-18 Novartis Ag Derivados de benzoxazolona como inhibidores de aldosterona sintasa
EA201101619A1 (ru) 2009-05-15 2012-05-30 Новартис Аг Производные 5-пиридин-3-ил-1,3-дигидроиндол-2-она и их применение в качестве модуляторов альдостеронсинтазы и/или cyp11b1
AU2010247414B2 (en) 2009-05-15 2013-08-01 Novartis Ag Aryl pyridine as aldosterone synthase inhibitors

Also Published As

Publication number Publication date
US20120071512A1 (en) 2012-03-22
CA2761858A1 (en) 2010-11-18
CN102459223A (zh) 2012-05-16
EA201101619A1 (ru) 2012-05-30
JP5654573B2 (ja) 2015-01-14
EP2430011A1 (en) 2012-03-21
MX2011012202A (es) 2011-12-08
JP2015034187A (ja) 2015-02-19
KR20120023091A (ko) 2012-03-12
JP2012526773A (ja) 2012-11-01
WO2010130794A1 (en) 2010-11-18
AU2010247412A1 (en) 2011-11-24
US8778972B2 (en) 2014-07-15
CN102459223B (zh) 2014-11-05
US20140275175A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
BRPI1012203A2 (pt) derivados de 5-piridin-3-il-1,3-di-hidro-indol-2-ona e seu uso como moduladores da aldosterona sintase e/ou da cyp11b1
BR112012008074A2 (pt) derivados de piridina e pirazina como moduladores de proteína quinase
BRPI0914223A2 (pt) derivados de tiofeno ou tiazol e seus usos como inibidores de p13k
BRPI0910439A2 (pt) derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk)
BR112013015234A2 (pt) derivados fosforosos como moduladores de receptor de quimiocina
BR112013014314A2 (pt) derivados de 6-amino-2-fenilamino-1h-benzimidazol-5-carboxamida e seu uso como inibidores de prostaglandina e2 sintase-1 microssômicas
EP2280954B8 (en) 6-pyridin-3-yl-3,4-dihydro-1h-quinolin-2-one derivatives and related compounds as inhibitors of the human aldosterone synthase cyp11b2
BRPI1010600A2 (pt) aril piridina como inibidores de aldosterona sintase
BRPI0810679A2 (pt) Derivados de 4-aza indol e seu uso como fungicidas
BRPI1010831A2 (pt) derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostéricos positivos de receptores de mglur2
DOP2011000397A (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
BRPI0910832A2 (pt) Derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk)
BR112012013175A2 (pt) 2-amino-5,5-diflúor-5,6-di-hidro-4h-oxazinas como inibidores de bace 1 e/ou bace 2
BRPI0815135A2 (pt) Derivados de azepina como inibidores de gama secretase.
BRPI1015038A2 (pt) derivados espiro azacíclicos como inibidores de hsl
BRPI0919322A2 (pt) derivados de glicosideo e usos dos mesmos como inibidores sglt
BR112012003089A2 (pt) ligação covalente reversível de moléculas funcionais
BRPI1012870A2 (pt) derivados de 1,2,4-triazolo[4,3-a]piridina e seu uso como moduladores alostéricos positivos de recpetores de mglur2
BRPI0911682A2 (pt) indóis como moduladores do recpetor da acetilcolina nicotínico subtipo alfa-71
BRPI1008749A2 (pt) Derivados de benzodiazepina
BRPI1012333A2 (pt) atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
BRPI0821836A2 (pt) Indóis macrocíclicos como inibidores do vírus da hepatite c
PL2424843T3 (pl) Pochodne imidazolowe i ich zastosowanie jako modulatorów kinaz zależnych od cykliny
BR112012008044A2 (pt) pteridinas e seu uso como agroquímicos
BRPI0816806A2 (pt) Derivados de azaciclil-isoquinolinona e isoindolinona como antagonista de histamina-3

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]